Preface — vii

Acknowledgments — ix

M. A. Reymond
1 Introduction — 1

M. A. Reymond
2 Peritoneal carcinomatosis: a neglected disease — 5
2.1 An unmet medical need — 5
2.2 Role of the physician in provision of care in advanced peritoneal cancer — 6
2.3 Palliative care in peritoneal carcinomatosis — 7

W. Solass and M. A. Reymond
3 Normal and diseased peritoneum — 11
3.1 Ontology — 11
3.2 Anatomy — 11
3.2.1 Blood supply — 12
3.2.2 Lymphatics — 13
3.2.3 Lymphatic stomata — 13
3.2.4 Milky spots — 14
3.2.5 Greater omentum — 14
3.2.6 Peritoneal nerves — 16
3.3 Physiology of peritoneum — 17
3.3.1 Peritoneum-plasma barrier — 17
3.3.2 Intraperitoneal Hydrostatic Pressure — 18
3.4 Pathophysiology of peritoneal carcinomatosis — 19
3.4.1 Epithelial-mesenchymal transition — 19
3.4.2 Interstitial intratumoral fluid pressure — 21
3.4.3 Ascites — 22
3.4.4 Hormonal changes — 24

W. Solass and M. A. Reymond
4 Diagnosis and staging of peritoneal carcinomatosis — 27
4.1 Diagnostic workup — 27
4.2 Imaging studies — 27
4.2.1 Computer tomography (CT scan) — 28
4.2.2 Magnetic Resonance Imaging (MRI) — 28
4.2.3 Ultrasound — 29
4.2.4 FDG-Positron emission tomography (PET) — 29
4.3 Diagnostic laparoscopy — 30
4.3.1 Peritoneal Cancer Index — 30
4.4 Peritoneal or pleural cytology — 32
4.4.1 Gastric cancer — 32
4.4.2 Ovarian cancer — 33
4.4.3 Colorectal cancer — 33

C. Demtroder, U. Giger-Pabst, W. Solass, and M. A. Reymond

5 Therapy of peritoneal carcinomatosis — 35
5.1 Systemic palliative chemotherapy — 35
5.2 Intraperitoneal chemotherapy — 36
5.3 Drug uptake into tumoral tissue — 37
5.3.1 Diffusion — 37
5.3.2 Convection — 39
5.4 Effect of peritonectomy on drug clearance — 40
5.5 Influence of intraperitoneal drug concentration — 41
5.6 Tissue penetration of various drugs — 41
5.6.1 Doxorubicin (see also page 199) — 42
5.6.2 Cisplatinum (see also page 198) — 43
5.6.3 Oxaliplatinum — 43
5.6.4 Taxanes (Paclitaxel, Docetaxel) — 43
5.7 Perioperative intraperitoneal chemotherapy — 44
5.7.1 CHPP — 44
5.7.2 NIPS — 45
5.7.3 EIPL — 46
5.7.4 EPIC — 46
5.8 Intraperitoneal chemotherapy for ascites — 47
5.9 Limitations of intraperitoneal chemotherapy — 47
5.9.1 Poor drug penetration — 47
5.9.2 Poor surface exposition — 48
5.9.3 Local toxicity — 48
5.9.4 Peritoneal sclerosis — 49
5.10 Intraperitoneal immunotherapy — 50
5.10.1 Catumaxomab — 50
5.10.2 Bevacizumab — 51
5.10.3 Immunoradiotherapy — 51
5.11 Intraperitoneal cytolytic virotherapy — 52
5.12 Nanodrugs — 52
5.13 Combined CRS with HIPEC — 53
5.13.1 Cytoreductive surgery (CRS) — 53
5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) — 54
5.13.3 Colorectal cancer — 55
5.13.4 Ovarian Cancer — 56
5.13.5 Gastric Cancer — 56
5.13.6 Learning curve and expertise — 57
5.13.7 Evidence of cost effectiveness — 57
5.13.8 Safety — 58
5.13.9 Indications for CRS and HIPEC — 58

W. Solass and M. A. Reymond
6 Assessing tumor response in peritoneal carcinomatosis — 67
6.1 Natural history of peritoneal carcinomatosis — 67
6.2 RECIST criteria — 67
6.2.1 RECIST criteria in peritoneal carcinomatosis — 68
6.3 Laparoscopy in peritoneal carcinomatosis — 68
6.4 Histology for determining tumor response — 69
6.5 Tumor markers for determining tumor response — 70
6.5.1 Gastric cancer — 70
6.5.2 Ovarian cancer — 70
6.5.3 Colorectal cancer — 71
6.6 Determining clinical benefit rate in peritoneal carcinomatosis — 71

7 Principle of therapeutic capnoperitoneum — 73
7.1 Material and methods — 74
7.1.1 Design of the prototype — 74
7.2 Results — 75
7.2.1 In vitro trial — 75
7.2.2 In vivo trial — 76
7.3 Discussion — 77
7.3.1 Increasing exposure of the peritoneal surface — 78
7.3.2 Increasing hydrostatic intraabdominal pressure — 78
7.3.3 Applications of therapeutic capnoperitoneum — 79

W. Solass, A. Hetzel, T. Schwarz, G. Nadiradze, E. Sagynaliev, and M. A. Reymond
8 PIPAC Technology — 83
8.1 Aerosol — 83
8.2 Pressure — 86
8.3 Micropump — 86
8.4 High-pressure injector — 87
8.5 Training and documentation — 89
8.6 Limited sales — 89
## Contents


9  **Preclinical experiments** — 91

9.1  Xenograft intraperitoneal model in the pig — 91

9.1.1  Material and methods — 92

9.1.2  Anesthesia — 92

9.1.3  Operative procedure: sigmoid colectomy — 92

9.1.4  Postoperative care — 93

9.1.5  Cell line — 93

9.1.6  Labeling of HeLa cells — 93

9.1.7  Immunohistochemistry — 94

9.1.8  In vitro study of chromate toxicity — 94

9.1.9  Intraoperative complications — 94

9.1.10  Port site recurrence — 94

9.1.11  Postoperative course — 95

9.1.12  Discussion — 96

9.2  Staining experiments with aerosolized methylene blue in the pig — 98

9.2.1  Introduction — 98

9.2.2  Material and Methods — 99

9.2.3  Results — 100

9.2.4  Discussion — 102

9.3  Ex vivo experiments with Dbait on diseased peritoneum — 106

9.3.1  Material and methods — 107

9.3.2  Study design — 108

9.3.3  Nebulizer — 108

9.3.4  Patient characteristics, cytoreduction, and intraperitoneal hyperthermic chemotherapy — 109

9.3.5  Tumor characteristics — 109

9.3.6  Experimental protocol — 109

9.3.7  Microscopic analysis — 109

9.3.8  Results — 110

9.3.9  Discussion — 112


10  **First PIPAC in-human application** — 115

10.1  Introduction — 115

10.2  Methods — 115

10.2.1  Patients — 115

10.2.2  Surgical procedures — 116

10.2.3  Safety and Efficacy assessments — 117

10.2.4  Histology and Immunohistochemistry — 117
10.2.5  Clinical Pharmacology — 117
10.3  Results — 117
10.3.1  Patient 1 — 117
10.3.2  Patient 2 — 118
10.3.3  Patient 3 — 119
10.4  Safety — 121
10.5  Clinical Pharmacology — 121
10.6  Discussion — 122

A. Blanco, U. Giger-Pabst, W. Solass, J. Zieren, and M. A. Reymond
11  Renal and liver toxicities — 127
11.1  Patients and methods — 127
11.1.1  Study Design — 127
11.1.2  Ethics — 128
11.1.3  Patients — 128
11.1.4  Therapy — 128
11.1.5  Sampling — 129
11.2  Statistical Analysis — 129
11.3  Results — 129
11.4  Discussion — 131

12  PIPAC in ovarian cancer — 135
12.1  Off-label use — 135
12.1.1  Patients and methods — 136
12.1.2  Results — 137
12.1.3  Discussion — 140
12.2  PIPAC-OV1: a Phase-2 trial in the third-line palliative situation — 143
12.2.1  Objectives — 143
12.2.2  Study design — 143
12.2.3  Target subject population — 143
12.2.4  Investigational product, dosage, and mode of administration — 144
12.2.5  Duration of treatment — 144
12.2.6  Endpoints — 144
12.2.7  Patient reported outcomes (PROs) — 145
12.2.8  Pharmacokinetics — 145
12.2.9  Safety — 145
12.2.10  Statistical methods — 145
12.2.11  Current stage — 145
12.3  PIPAC-OV2: a Phase-1 dose-finding study — 145
12.4  PIPAC-OV3: a prospective Phase-2-3 randomized trial — 146
13 PIPAC in gastric cancer — 147
13.1 Off-label use — 148
13.2 Results — 149
13.3 Discussion — 154
13.4 PIPAC-GA1: a Phase-2 trial in the third-line palliative situation — 158
13.4.1 Objectives — 158
13.4.2 Study design — 159
13.4.3 Target subject population — 159
13.4.4 Investigational product, dosage and mode of administration — 159
13.4.5 Duration of treatment — 159
13.4.6 Study endpoints — 159
13.4.7 Current stage — 160

14 PIPAC in colorectal cancer — 161
14.1 Patients and methods — 162
14.2 Results — 164
14.3 Discussion — 167

15 PIPAC in mesothelioma — 171
15.1 Patients and methods — 171
15.2 Results — 172
15.3 Conclusions — 172

16 Quality of Life after PIPAC — 175

17 PIPAC and HIPEC — 179
17.1 PIPAC as a neoadjuvant therapy before HIPEC — 181

18 Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) — 183
18.1 Patients — 184
18.2 Technique — 184
18.2.1 First in-human use — 184
18.3 Results — 185
M. A. Reymond

22 Outlook — 215
22.1 Radio- and Chemosensibilizers — 216
22.2 Nanodrugs — 216
22.3 Multimodal therapy — 216
22.4 Preventive application in cancer — 217
22.5 Applications outside cancer therapy — 217

U. Giger-Pabst and M. A. Reymond

23 How to start a PIPAC program at your own institution? — 219
23.1 Regulatory aspects — 219
23.1.1 Compassionate use program or off-label use? — 219
23.1.2 Drug or medical product? — 220
23.1.3 CE certification — 220
23.1.4 Reimbursement — 220
23.2 Technology access — 221
23.3 Occupational health and safety — 221
23.4 In-house Information and training — 222
23.5 Research — 222

U. Giger-Pabst and M. A. Reymond

24 Training and Standard Operating Procedures — 223
24.1 Training — 223
24.2 Safety checklist for PIPAC — 223
24.3 Peritoneal and pleural carcinomatosis index — 225
24.3.1 Extent of Pleural Carcinomatosis (EPC) score — 225
24.4 Registry data — 225

Index — 227